Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05517603 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients
A Phase 1 study, sponsored by AnnJi Pharmaceutical Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT05517603 is a Phase 1 study that has completed, run by AnnJi Pharmaceutical Co.. The registered enrollment target is 25 participants.
The verdict
NCT05517603, a Phase 1 study, has completed, sponsored by AnnJi Pharmaceutical Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a phase 1/2a randomized, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of study drug AJ201 in subjects with Spinal and Bulbar Muscular Atrophy (SBMA).
Interventions
- DRUG Placebo
- DRUG AJ201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2024-04-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05517603
The ClinicalTrials.gov registry entry for NCT05517603 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AnnJi Pharmaceutical Co., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05517603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05517603 about?
NCT05517603 is a clinical study titled "A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients". This is a phase 1/2a randomized, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of study drug AJ201 in subjects with Spinal and Bulbar Muscular Atrophy (SBMA).
What is the current status of trial NCT05517603?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2023-02-28. Estimated completion is 2024-04-08.
What interventions are being tested in trial NCT05517603?
The interventions under investigation include: Placebo (DRUG), AJ201 (DRUG).
Who is sponsoring clinical trial NCT05517603?
This trial is sponsored by AnnJi Pharmaceutical Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.